Advertisement
BDX vs RVTY
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. Revvity, Inc. (RVTY) Stock Comparison
Key Takeaways
- BDX boasts a market cap of $42.47 billion, dwarfing RVTY's $9.69 billion, reflecting greater scale in the medtech sector.
- BDX offers a lower forward P/E ratio (price-to-earnings ratio) of 11.89 versus RVTY's 16.05, indicating potentially better valuation for value-oriented investors.
- Recent market activity shows RVTY with stronger year-to-date gains at 10.28% compared to BDX's 1.51%, highlighting momentum differences.
- BDX provides a higher dividend yield of 2.81% versus RVTY's 0.32%, appealing to income-focused traders.
- Both stocks exhibit low beta values, with BDX at 0.28 and RVTY at 1.05, but BDX demonstrates superior stability in volatile conditions.
- Analyst price targets suggest comparable upside, with BDX at $191.46 and RVTY at $113.93 from current levels.
Introduction
This stock comparison pits BDX, a leader in medical devices and diagnostics, against RVTY, a provider of life sciences solutions and diagnostics tools. Both operate in the healthcare sector, benefiting from steady demand for innovation amid evolving global health needs. Traders seeking relative performance insights and investors evaluating medtech exposure will find value here, particularly in assessing valuation, momentum, and risk in recent market conditions. This analysis draws on key metrics and developments to illuminate contrasts in their market positioning.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) specializes in medical technology, including syringes, catheters, and diagnostic systems. In recent weeks, its stock has experienced mild weakness, trading around $149 amid broader sector pressures. Year-to-date returns stand at 1.51%, with a one-year gain of 14.65%, reflecting resilience despite a 52-week range from $127.59 to $187.35. Sentiment has been influenced by strong Q1 fiscal 2026 results in February, featuring revenue growth and an earnings beat, alongside innovations like advanced vascular access technology and employee well-being recognitions. Dividend declarations and share buybacks further support stability, though upcoming Q2 earnings previews signal potential declines, tempering near-term optimism.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY) focuses on life sciences reagents, services, and software for drug discovery and diagnostics. Recent market activity has shown positive momentum, with the stock around $87, posting year-to-date returns of 10.28% and a one-year increase of 6.43% within a 52-week range of $81.22 to $118.30. Key drivers include product launches such as Signals BioDesign for molecular cloning and presentations at investor conferences. Shareholder approvals and quarterly dividend hikes bolster confidence ahead of Q1 2026 earnings on May 5. While quarterly revenue growth reached 5.90%, mixed analyst notes on valuation have introduced caution in recent trading.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of top-performing AI trading bots from its library of hundreds, which collectively trade thousands of tickers across diverse strategies, timeframes, and styles. Only the most suitable for prevailing market conditions earn a spot among the 25 highlighted bots, showcasing impressive stats like annualized returns ranging from 32% to 126%, win rates of 50-68%, profit factors up to 3.33, and profit-to-drawdown ratios exceeding 17 in some cases. These bots employ tactics from semiconductor momentum to volatility plays and small-cap trends, with average trade durations from minutes to days and drawdowns managed below $12,000 in many portfolios. Explore these tools to align automated trading with current opportunities.
Head-to-Head Comparison
BDX and RVTY both thrive in healthcare but diverge in scale and focus: BDX's device-centric model drives consistent revenue ($21.92B ttm), while RVTY's tools emphasize research growth ($2.86B ttm). Growth drivers differ, with RVTY showing faster quarterly revenue expansion (5.90% vs. 1.60%), but BDX excels in profitability margins and ROE (6.96% vs. 3.22%). Recent momentum favors RVTY YTD, yet BDX leads over one year. Risk profiles highlight BDX's lower beta and debt/equity (77.28% vs. 46.87%), suiting conservative positioning, while RVTY offers higher sector exposure to biotech innovation. Market sentiment tilts toward value for BDX and growth for RVTY, presenting trade-offs in stability versus upside potential.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BDX based on its superior forward valuation, dividend yield, low volatility, and established trend consistency amid recent market activity. While RVTY displays stronger short-term momentum and growth catalysts, BDX's scale and stability position it favorably for probabilistic outperformance in varied conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BDX is a Hold and RVTY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 1 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s).
- BDX’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 2 TA indicator(s) are bullish while RVTY’s TA Score has 4 bullish TA indicator(s).
- BDX’s TA Score: 2 bullish, 7 bearish.
- RVTY’s TA Score: 4 bullish, 5 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а -4.18% price change this week, while RVTY (@Medical Specialties) price change was -3.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.06%. For the same industry, the average monthly price growth was +5.15%, and the average quarterly price growth was -12.66%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.17%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was -2.29%.
Reported Earning Dates
BDX is expected to report earnings on Jul 30, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.06% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.17% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BDX | RVTY | BDX / RVTY | |
| Capitalization | 39.7B | 11.2B | 354% |
| EBITDA | 4.97B | 773M | 643% |
| Gain YTD | -5.961 | 1.247 | -478% |
| P/E Ratio | 25.13 | 48.08 | 52% |
| Revenue | 22.2B | 2.9B | 765% |
| Total Cash | N/A | 860M | - |
| Total Debt | 17.3B | 3.35B | 516% |
BDX | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 89 | |
PRICE GROWTH RATING 1..100 | 58 | 38 | |
P/E GROWTH RATING 1..100 | 75 | 32 | |
SEASONALITY SCORE 1..100 | 20 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (5) in the Medical Specialties industry is in the same range as RVTY (15). This means that BDX’s stock grew similarly to RVTY’s over the last 12 months.
BDX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RVTY (100). This means that BDX’s stock grew similarly to RVTY’s over the last 12 months.
BDX's SMR Rating (87) in the Medical Specialties industry is in the same range as RVTY (89). This means that BDX’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (38) in the Medical Specialties industry is in the same range as BDX (58). This means that RVTY’s stock grew similarly to BDX’s over the last 12 months.
RVTY's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for BDX (75). This means that RVTY’s stock grew somewhat faster than BDX’s over the last 12 months.
| BDX | RVTY | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 48% | 1 day ago 66% |
| Momentum ODDS (%) | 1 day ago 47% | 1 day ago 74% |
| MACD ODDS (%) | 1 day ago 41% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 45% | 1 day ago 67% |
| TrendMonth ODDS (%) | 1 day ago 48% | 1 day ago 60% |
| Advances ODDS (%) | 14 days ago 43% | 3 days ago 65% |
| Declines ODDS (%) | 3 days ago 43% | 17 days ago 67% |
| BollingerBands ODDS (%) | 1 day ago 58% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 39% | 1 day ago 52% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | -2.45% | ||
| COO - BDX | 53% Loosely correlated | -3.41% | ||
| TMO - BDX | 50% Loosely correlated | -2.31% | ||
| CNMD - BDX | 48% Loosely correlated | -7.12% | ||
| BAX - BDX | 46% Loosely correlated | -5.23% | ||
| RVTY - BDX | 45% Loosely correlated | -3.36% | ||
More | ||||